Portal de Periódicos da CAPES

New-onset IgG autoantibodies in hospitalized patients with COVID-19

2021; Nature Portfolio; Volume: 12; Issue: 1 Linguagem: Inglês

10.1038/s41467-021-25509-3

2041-1723

Sarah E. Chang, Allan Feng, Wenzhao Meng, Sokratis A. Apostolidis, Elisabeth Mack, Maja Artandi, Linda Barman, Kate Bennett, Saborni Chakraborty, Iris Chang, Peggie Cheung, R. Sharon Chinthrajah, Shaurya Dhingra, Evan Do, Amanda Finck, Andrew Gaano, Reinhard Geßner, H.M. Giannini, Joyce González, Sarah Greib, Margrit Gündisch, Alexander Hsu, Alex Kuo, Monali Manohar, Rong Mao, Indira Neeli, Andreas Neubauer, Oluwatosin Oniyide, Abigail E. Powell, Rajan Puri, Harald Renz, Jeffrey M. Schapiro, Payton A. Weidenbacher, Richard Wittman, Neera Ahuja, Ho‐Ryun Chung, Prasanna Jagannathan, Judith A. James, Peter S. Kim, Nuala J. Meyer, Kari C. Nadeau, Marko Radic, William H. Robinson, Upinder Singh, Taia T. Wang, E. John Wherry, Chrysanthi Skevaki, Eline T. Luning Prak, Paul J. Utz,

Diabetes and associated disorders

COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.